Trial results for semaglutide in Chilean participants with Type 2 Diabetes were posted on ClinicalTrials.gov on 2025-02-10. The study demonstrated a mean reduction in HbA1c of 1.6% and a mean body weight loss of 5.3 kg over approximately 24 weeks.
Background
Semaglutide is a medication used in the management of Type 2 Diabetes Mellitus. This study specifically investigated its use in a Chilean population.
Trial design
The completed Phase 4 study (NCT05533632) enrolled 104 participants with Type 2 Diabetes Mellitus in Chile. The trial investigated the safety and tolerability of once-weekly subcutaneous semaglutide, with doses adjusted by the study doctor according to individual participant needs. The study duration was approximately 24 weeks.
Key results
The trial reported 45 adverse events (AEs). Key efficacy measurements included:
- Mean change in Glycosylated Haemoglobin (HbA1c) was -1.6% (Standard Deviation: 1.0).
- 52 participants achieved HbA1c less than 7.0%, while 40 participants did not.
- Mean change in Fasting Plasma Glucose (FPG) was -26.2 mg/dL (Standard Deviation: 61.3).
- Mean change in Body Weight was -5.3 kg (Standard Deviation: 4.3).
- 56 participants achieved greater than or equal to 5% weight reduction, while 36 participants did not.
- 17 participants achieved greater than or equal to 10% weight reduction, while 75 participants did not.
- Mean change in Waist Circumference was -5.7 cm (Standard Deviation: 5.7).
- Mean change in Total Cholesterol was -14.1 mg/dL (Standard Deviation: 26.0).
What this means
The results from this Phase 4 study suggest that semaglutide effectively improves glycemic control, reduces body weight, and positively impacts other metabolic parameters such as waist circumference and total cholesterol in Chilean participants with Type 2 Diabetes. These findings, observed in a real-world setting, reinforce the known benefits of semaglutide for managing Type 2 Diabetes and its associated metabolic factors.
Source
The information for this article was sourced from ClinicalTrials.gov, a public database of clinical studies. The trial results for study NCT05533632, titled "Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes," were posted on 2025-02-10 on clinicaltrials.gov.